Zacks.com on MSN9h
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline ...
Medscape2d
When or Whether to Give Immunotherapy in Early Breast Cancer
Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...
emjreviews.com5d
New Approach Offers Hope for Drug-Resistant Lung Cancer
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
Science Daily7d
How studying fruit flies can help us understand congenital defects
Researchers elucidated the molecular details of how Drosophila larval epidermal cells (LECs) undergo cell death in a controlled manner to regulate epithelial tissue remodeling. Specifically, lower ...
centerforbiosimilars2d
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...
News Medical on MSN3d
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...
Puma Biotechnology initiates ALISertib in CAncer trial
Puma Biotechnology (PBYI) announced the initiation of its ALISertib in CAncer Phase II trial of alisertib in combination with endocrine therapy ...
AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...